3-(Arylamino)-3-phenylpropan-2-olamines as a new series of dual norepinephrine and serotonin reuptake inhibitors.
Article Details
- CitationCopy to clipboard
Vu AT, Cohn ST, Terefenko EA, Moore WJ, Zhang P, Mahaney PE, Trybulski EJ, Goljer I, Dooley R, Bray JA, Johnston GH, Leiter J, Deecher DC
3-(Arylamino)-3-phenylpropan-2-olamines as a new series of dual norepinephrine and serotonin reuptake inhibitors.
Bioorg Med Chem Lett. 2009 May 1;19(9):2464-7. doi: 10.1016/j.bmcl.2009.03.054. Epub 2009 Mar 18.
- PubMed ID
- 19329313 [ View in PubMed]
- Abstract
A series of 3-(arylamino)-3-phenylpropan-2-olamines was prepared and screened for their ability to inhibit monoamine reuptake. A number of analogues displayed significant dual norepinephrine and serotonin reuptake inhibition. Compounds in this class exhibited minimal affinity for the dopamine transporter.
DrugBank Data that Cites this Article
- Binding Properties
Drug Target Property Measurement pH Temperature (°C) Atomoxetine Sodium-dependent noradrenaline transporter IC 50 (nM) 3 N/A N/A Details Atomoxetine Sodium-dependent serotonin transporter IC 50 (nM) 48 N/A N/A Details Desipramine Sodium-dependent noradrenaline transporter IC 50 (nM) 3.4 N/A N/A Details Duloxetine Sodium-dependent noradrenaline transporter IC 50 (nM) 4 N/A N/A Details Duloxetine Sodium-dependent serotonin transporter IC 50 (nM) 3 N/A N/A Details Fluoxetine Sodium-dependent serotonin transporter IC 50 (nM) 10 N/A N/A Details Mazindol Sodium-dependent dopamine transporter IC 50 (nM) 22 N/A N/A Details